20/20 BIOLABS, INC. (AIDX)

Every figure this model derived for AIDX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 4,546,140 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 5,075,623 AssetsCurrent 2026-06-30
current liabilities 2,551,236 LiabilitiesCurrent 2026-06-30
equity 1,620,700 StockholdersEquity 2026-06-30
interest expense 156,207 InterestExpenseNonoperating 2025-12-31
ocf -1,919,720 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 2,045,133 Revenues 2025-12-31
sbc 516,180 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up AIDX on one particular measure came for.

RatioValue
cash operating margin-134.54
current ratio2.44
current ratio reported1.99
dilution pct2.7
fcf margin-93.87
interest cover-21.32
operating margin-162.87
owner earnings margin-119.11
revenue growth16.71
revenue growth per share13.63
rule of 40-146.16
sbc pct revenue25.24

What to be careful about

What this model itself distrusts about AIDX's figures. Written by the derivation as it ran, not added afterwards.